Agreement on the proposed Critical Medicines Act (CMA) represents an important step for boosting the EU pharma sector.

AstraZeneca has received approval from the EDE in the UAE for Baxfendy, a medicine using the active ingredient baxdrostat, for uncontrolled hypertension.

Isomorphic Labs has secured $2.1bn in funding to expedite its transition from developing AI models to deploying them on a larger scale.

Following news that started brewing last week, Dr Marty Makary has officially resigned from his post as commissioner of the US Food and Drug Administration (FDA), with Kyle Diaman ...

GSK has partnered with SBP Group, via its subsidiary CTTQ, to expedite the launch of bepirovirsen for chronic hepatitis B patients in China.

An indirect comparison highlights the potential of BridgeBio's Attruby to best Pfizer’s tafamidis in frontline ATTR-CM.

Partner Therapeutics has received FDA approval for Bizengri to treat adults with advanced, unresectable or metastatic cholangiocarcinoma harbouring an NRG1 gene fusion and who have progressed on or ...

BMS and Hengrui will trade the greater Chinese and US rights to certain programmes, while joining forces to progress five innovative assets.

Approved drugs could be expanded into disease areas with limited commercial potential, providing supporting data is available.

Manufacturing deals saw an unusual burst of recent activity, with a spike in the number of CDMOs acquiring facilities from pharma companies.

Cellular Intelligence has licensed Novo Nordisk’s cell therapy programme for Parkinson’s disease, seven months after the Danish drugmaker wound down operations with the modality. Cellular Intelligence ...

Angelini Pharma has signed a definitive agreement to acquire Catalyst Pharmaceuticals for a total equity value of nearly $4.1bn.